Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"(EN)A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation."
I wonder how much anxiety or agitation is worth in dollars and cents.
BB
Galileo Galilei.
I never pass up an opportunity to look up a good quote.
BB
Might I suggest a recording device (just for your notes).
BB
Thanks, good to hear.
BB
I would like to know if it is Anavex's intent to become a BP.
BB
If you read Xena's Compiled Due Diligence 03/17/19 post in the sticky area you'll be more than up to date.
Link below.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147597303
BB
Would carrying you on our shoulders with the first pill held high be overkill?
BB
Smart move.
BB
That's what I've thought all along.
No doctor's going to prescribe a MS combo drug off label so Biogen only gets a very defined market.
This would solve all our financial concerns.
Fire up the whole damn pipeline!
BB
We still have plenty of company.
From 10/3/18
"More than 400 clinical trials are currently looking at new treatments for Alzheimer’s disease (AD) and many of them are actively recruiting. Many of these studies are based on decreasing the harmful effects of a toxic protein called amyloid-beta in the brain, but others reflect a broadening range of possible treatment approaches based on other theories about AD.
Pharmaceuticals under study include both medications and dietary supplements. In addition to these, many studies are exploring non-pharmaceutical strategies. These include behavioral interventions, exercise, and physical treatments including acupuncture, electromagnetic devices, and even surgery. The representative trials discussed here are found in the registry of ongoing studies located at www.clinicaltrials.gov, which can be accessed for information about activity and enrollment."
BB
Couldn't have said it better if I knew what it was.
BB
On the plus side, we'll get to see how A2-73 works on humans in regard to seizures and motor skills!
BB
I believe it was Xena who postulated the AD trial is destined for Phase 4 and the foot dragging is intentional.
I find that intriguing.
Does anyone else believe that?
BB
I believe they mentioned PD was dosing and AZ had screened 80 in the same paragraph.
The opportunity was there.
BB
I was pondering that this weekend.
Are the uses for the preferreds finite and known, or could Dr. Missling in a stroke of brilliance pull a rabbit out of his hat?
BB
This question has been answered up front.
"All patients who participate in the study will be eligible to receive ANAVEX(R)2-73 under a voluntary open label extension protocol."
BB
I was thinking first patient dosed in Rett trial.
BB
Big thoughts.
BB
You make an interesting point I hadn't thought of.
By September some trial participants might have an additional 6 months of dosage under their belts.
If a regulatory body was sitting on the fence the additional evidence might help.
BB
Not sure I buy that.
Anavex asked for the very same 10 million 2 years ago.
This was before Ariana, 80/20 responders rate, gut microbiome,...
DR. Missling himself said he was only somewhat confident prior to all that.
I think he's simply looking for the maximum amount of arrows in his quiver and now is the time to lobby for them.
BB
About a week ago Biostock surmised the preferreds were a lock based on how Dr. Missling/Anavex were talking more boldly.
This tells me no.
BB
Do you think we should start a hedge fund using this technique?
If history is any guide they'll come in droves.
BB
Thanks to the first in first out rule and some largely unsuccessful attempts at trading AVXL, my TD account shows a tidy profit in the stock.
BB
But why ask for extension?
If positive things are happening why not halt or let it run out and recommend for approval?
BB
Anavex aside, I think the world is hellbent on making progress against Alzheimer's.
https://www.sciencedaily.com/releases/2019/03/190311090958.htm
Not finding that.
Could you please give me a page number.
BB
I'm lost.
I read Xena's link but don't understand why our relationship with Cantor has changed or is over.
BB
I don't think the p2 participants participate in the p3 trial.
Considering how ill these people are I couldn't imagine after the trial is over they'd just be handed their hat and shown the door.
BB
Weren't you the one who said the people running our end of the trial are top notch?
BB
"Single payer countries have a greater financial incentive to adopt cost effective new treatments."
You're right of course.
I'm just biased by the U.S. way of doing things.
Pay the most and get the worst result.
BB
Great link. Gives me hope.
30-0 would hint intelligence at work.
BB
I don't really think we've given enough air time to this problem.
What if Spain is also populated with old school thought and while we might show some intriguing results they insist on a phase 3?
And considering the foot dragging on Rett might the same not occur?
Many on this board think our trial results will be so compelling the various regulatory bodies will have no choice but to recommend immediate approval.
I wish the "powers that be" were so humble, honest and clear thinking on my home planet.
BB
Thoughts as to whether A3-71 would be effective on the 20% that A-2-73 is not effective on?
BB
What about laying hens?
BB
Remember the list of unexpected stuff from the 2a trial?
I wonder what new goodies will show up with hundreds of people taking A2-73.
BB
I voted yes to the preferred so you owe me a Bacon McDouble® and a small fries.
BB
Or it could be we don't have the votes and Anavex is begrudgingly releasing this in an attempt to garner them.
BB
Wonder if Cantor had there finger near the sell button at the open.
Doesn't matter, just wondering.
I would love to hear how the original 2a trial participants are doing.
Would also like to know if he considers the preferred crucial.
Regards,
BB
If Dr. Missling sensed someone was accumulating shares with intent, would quickly partnering with someone make us less attractive?
BB